Cyclo Therapeutics Inc - SIC # 2833 - MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS

Ticker Exchange SIC # Website Latest Ticker
CYTH Nasdaq 2833 https://www.cyclotherapeutics.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cyclo Therapeutics Inc

Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference - Sep 21st, 2023 1:35 pm
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement - Sep 21st, 2023 12:05 pm
Cyclo Therapeutics Reports Second Quarter 2023 Financial Results - Aug 15th, 2023 12:05 pm
Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc. - Aug 2nd, 2023 12:16 pm
Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 - Jun 29th, 2023 5:32 pm
Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update - Jun 13th, 2023 8:01 pm
Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol® Cyclo™ for Alzheimer’s Disease - Jun 12th, 2023 12:05 pm
Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement - Jun 5th, 2023 12:05 pm
Cyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results - May 15th, 2023 12:05 pm
Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL) - May 2nd, 2023 12:12 pm
Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Apr 21st, 2023 12:05 pm
Cyclo Therapeutics Provides Business Update and Reports Full Year 2022 Financial Results - Mar 20th, 2023 12:05 pm
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th - Jan 11th, 2023 6:00 pm
Cyclo Therapeutics Provides Clinical Program Update and Highlights Recent Achievements - Jan 11th, 2023 1:05 pm
Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event - Jan 10th, 2023 1:05 pm
Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease - Jan 9th, 2023 1:05 pm
Cyclo Therapeutics Announces Closing of $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - Jan 4th, 2023 9:05 pm
Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting - Jan 4th, 2023 1:05 pm
Cyclo Therapeutics Announces $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - Dec 30th, 2022 1:00 pm
Cyclo Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Achievements - Nov 11th, 2022 1:05 pm